Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy
Alok Khorana
42d ago
Another failed ph 3 #PancreaticCancer study - Halo seemed to have no effect whatsoever
0